Galenea Corp., a leader in the rapidly emerging field of synaptic transmission, announced the publication of a paper in PLoS ONE demonstrating the development and validation of the MANTRA (Multiwell, Automated NeuroTRansmission Assay) system, Galenea's proprietary technology that enables high throughput screening of synaptic function directly on cultured primary neurons.